Eloralintide: Weight-Loss Evidence, Side Effects and Phase 3 Trials

Eloralintide is Lilly’s investigational, once-weekly amylin receptor agonist, also called LY3841136. Its published Phase 2 obesity trial found approximately 9%–20% mean weight loss over 48 weeks across treatment groups. Phase 3 studies are recruiting, but those registrations are not results or approval. The separate combination with tirzepatide is called EloraTZP. Understanding which treatment, population and analysis produced a headline is essential to interpreting this emerging evidence. 1–6

Eloralintide at a glance

Sources: the published Phase 2 report, discovery study, current sponsor explanation and trial registries. Evidence checked November 11, 2026. 1–6

What eloralintide is and how it works

Amylin is a hormone involved in appetite and satiety after eating. Eloralintide is designed to activate amylin receptors and is being investigated as a different approach to weight management from medicines whose primary targets are GLP-1 or GIP. Lilly describes it as a selective amylin receptor agonist. “Selective” describes a pharmacological property; it does not itself establish a superior clinical safety profile. 3,4

The discovery paper reports preferential activation of human AMY1R in cell assays, alongside animal experiments and an early human study. These are different layers of evidence. A laboratory receptor result explains why researchers investigate a molecule. An animal experiment can explore a mechanism. Neither establishes the amount of weight a person will lose or how often a particular adverse event will occur in clinical care. 3

A useful way to read this research is to keep three questions separate: does the molecule engage its intended pathway, does a controlled human trial show a measurable benefit, and does the overall balance of benefits and harms support a clinical indication? The eloralintide development program is progressing through those questions. The existence of a plausible mechanism should never be used to skip the latter two.

For context on the related amylin pathway and another development program, see our cagrilintide guide. For the established incretin framework, see GLP-1 medications for weight loss.

What the published Phase 2 trial actually tested

The 48-week study enrolled 263 adults at 46 US research centers. Participants had obesity, or overweight with a weight-related comorbidity, and did not have type 2 diabetes. They were randomly assigned to placebo or one of six eloralintide groups. The primary endpoint was percentage change in body weight at week 48. The peer-reviewed paper appeared online in November 2025 and identifies Eli Lilly as the funder. 1

Randomization and a placebo comparator make this stronger evidence than testimonials or a before-and-after photograph. They do not remove every uncertainty. This was a relatively small trial divided among seven groups. Its participants, follow-up period and treatment conditions define the setting in which the result was measured. It does not directly answer every question about longer-term treatment, other populations or switching from another medicine.

The table below uses ClinicalTrials.gov’s posted least-squares mean results, rather than silently mixing decimals from different summaries. The sponsor announcement reports 9.5% for the 1 mg group and 16.4% for the final escalation group; the registry displays 9.4% and 16.5%, respectively. The published abstract rounds most active-arm results to whole percentages. Those source differences are small, but the table keeps one source convention throughout. 1,2,7

These are randomized research arms, not a recommended starting dose or an escalation schedule. The registry labels the outcome as a model-based least-squares mean; the publication and sponsor describe the principal efficacy analysis as an efficacy estimand. 1,2,7

How to interpret “20% weight loss”

An estimand specifies the treatment effect a study aims to estimate. Lilly’s description of this trial’s efficacy estimand assumes participants remained on the study intervention over 48 weeks, with possible interruptions or dose modifications. That makes the headline useful for understanding the study’s efficacy question, while leaving a separate question about outcomes under routine use and discontinuation. 7

The 20.1% figure is a group estimate for a particular arm. It is not a minimum, an individual forecast or evidence that every participant lost that amount. Averages compress variation. When evaluating an emerging treatment, the next useful questions are how outcomes were distributed, how missing observations were handled, how many people completed treatment and why others stopped.

Comparing the number with a percentage from an unrelated trial adds further uncertainty. A longer trial gives a treatment more time to show a change; different diabetes status, baseline characteristics, background care and statistical assumptions can also change the result. A spreadsheet that places percentages in descending order cannot resolve those differences.

Our editorial interpretation is that these findings justify close attention to the larger development program. They do not establish that eloralintide is the best weight-loss treatment, that it is appropriate for a particular person or that the same result will persist after treatment ends. Those are distinct claims requiring distinct evidence.

Side effects and the limits of the tolerability claim

The Phase 2 publication reports nausea and fatigue among the most common adverse events. Nausea ranged from 11% to 64% across active groups, compared with 14% on placebo; fatigue ranged from 0% to 46%, compared with 12%. These ranges combine different randomized groups. They should not be presented as one pooled probability for every future patient. 1

The sponsor reports more gastrointestinal symptoms and fatigue at higher doses and lower incidence with slower escalation. That is a finding about the protocols tested. It does not supply a validated home titration method, and a lower event rate in one small arm does not prove the molecule will be easier to tolerate than an approved alternative. 7

Earlier evidence also needs its own context. A 12-week Phase 1 study randomized 100 participants and reported weight reductions alongside adverse-event observations. A short early study is useful for assessing initial pharmacology and identifying signals; it cannot establish rare-event risk or the safety of years of use. It should not replace the larger, longer evidence simply because its tolerability figures look more favorable. 8

When reading a safety headline, ask whether it describes any adverse event, a serious adverse event, an event judged treatment-related or an event that caused discontinuation. These are different categories. Also ask whether percentages are pooled across doses or reported separately. An apparent discrepancy can reflect different denominators rather than a genuinely conflicting result.

The general peptide safety guide explains why evidence about a named investigational molecule and evidence about the contents of a particular product must remain separate.

Eloralintide versus EloraTZP

Eloralintide is one investigational molecule. EloraTZP is the investigational combination of eloralintide and tirzepatide. Tirzepatide acts at GIP and GLP-1 receptors, so the combination brings together amylin and incretin pathways. Results for a combination cannot be assigned to its amylin component alone. 4

In September 2026, Lilly presented a separate 48-week Phase 2 study in adults with type 2 diabetes and obesity or overweight. The presentation reports 367 randomized participants across ten arms. Its highest reported combination weight reduction was 23.3% under the efficacy estimand, compared with 14.8% for the tirzepatide 15 mg arm and 3.0% for placebo. This is sponsor-presented conference evidence, distinct from the peer-reviewed 263-person monotherapy trial. 9

That distinction matters in both directions. The combination study provides within-study comparison information that a collection of unrelated monotherapy trials cannot. But it also studies a different population and a different intervention. A reader should not replace “eloralintide” with “EloraTZP” in a headline while retaining the original trial’s participant count, safety figures or weight-loss estimate.

The presentation also reports adverse events and treatment discontinuations across the study arms. Those results need to be read alongside efficacy rather than treating the largest weight reduction as the complete result. Combination safety findings should not be converted into a monotherapy event rate. 9

For established background on tirzepatide rather than the investigational combination, see our tirzepatide reference.

What Phase 3 registration tells us today

Two current registry records provide a concrete view of the monotherapy program. As checked on November 11, 2026, ENLIGHTEN-1 and ENLIGHTEN-2 both list recruitment. Their enrollment figures are estimates, and their primary completion dates are projections. They are not reports of completed Phase 3 efficacy. 5,6

ENLIGHTEN-1 also lists outcomes including body-fat change and progression to type 2 diabetes in participants with prediabetes. ENLIGHTEN-2 includes glycemic and other metabolic measures. A registered outcome identifies a question investigators intend to examine; it does not establish a favorable answer. 5,6

This is a selected view of two studies, not a claim to enumerate the entire ENLIGHTEN or combination program. Recruitment, locations and projected dates can change. Trial participation questions belong with the current registry and study site. No launch date follows automatically from the month shown under estimated primary completion.

Comparison with cagrilintide, semaglutide and tirzepatide

The clearest comparison starts with the intervention. Cagrilintide and eloralintide belong in the amylin discussion, while semaglutide and tirzepatide belong in the incretin discussion. CagriSema and EloraTZP are combinations and should be identified by their actual components. Mechanism helps organize the landscape; clinical comparisons still require attention to the trial design. 3,4 Our cagrilintide guide covers that molecule and its combination context.

For a useful comparison, write down the population, duration, comparator, analysis and discontinuations before looking at the largest percentage. If any of these fields are missing, “better” is underspecified. Better could mean greater average weight reduction, fewer symptoms, more people remaining on treatment, a different health outcome or easier access. One figure rarely answers all of them.

There is also a difference between a treatment being scientifically interesting and being available for routine prescribing. Lilly continues to describe eloralintide and EloraTZP as investigational. A proposed approval date, retail price or insurance benefit cannot be inferred from the Phase 2 findings. This article does not treat a research-vendor listing as an approved medicine. 4

See our tirzepatide versus semaglutide comparison for a separate discussion of those medicines. It should not be read as a head-to-head comparison with eloralintide.

Questions worth carrying into the next evidence update

The most useful next update will do more than replace one weight-loss percentage. It should clarify how the larger studies balance efficacy, tolerability, treatment persistence and outcomes important to participants. Our editorial checklist for future coverage is:

• Population: Who was included, and which groups remain underrepresented?
• Analysis: Are results reported under an adherence-assuming analysis, a treatment-policy analysis or both?
• Persistence: How many participants remained on treatment, and what caused discontinuation?
• Safety: Which events were serious, treatment-related or concentrated in a particular arm?
• Duration: What happened over longer follow-up and, if measured, after treatment stopped?
• Regulatory decision: Is the update a registration, a sponsor announcement, a publication, an application or an actual approval?

These questions keep the evidence useful without pretending that a development milestone supplies an individual treatment decision. Someone considering currently available care can use them to frame a discussion with their clinician. Someone researching a trial can use them to identify the relevant protocol and the questions to ask the study team.

Frequently asked questions

Is eloralintide the same as LY3841136?

Yes. LY3841136 is the development identifier used in the discovery literature and clinical trial records. Searching both names helps connect earlier work with later publications. It does not mean every product using that name is the study material. 2–4

Is eloralintide approved, and when will it launch?

The current sponsor sources reviewed describe it as investigational, and the two Phase 3 records above list recruitment. These sources do not establish an approved consumer product or a launch date. Projected trial completion dates are not approval deadlines. 4–6

Does eloralintide cause fewer side effects than GLP-1 medicines?

The early findings do not establish that broad claim. Different doses, escalation approaches, populations and reporting methods complicate comparisons. Read adverse-event and discontinuation data alongside efficacy, and distinguish a direct randomized comparison from figures collected across separate trials. 1,7–9

Can the published doses be used as a personal protocol?

The numbers identify research groups and help readers understand the results. They do not establish an approved starting dose, a switching method, or how to combine separate products. The trial protocol and its oversight are part of the intervention being studied.

What would make this article change?

A new peer-reviewed trial, updated registry results, a material safety finding or a regulatory decision could change the evidence summary. We distinguish the date a source was published from the date this page was checked, so an editorial update is not mistaken for a new clinical result.

References

1. Billings LK et al. Eloralintide: 48-week randomized Phase 2 trial. The Lancet, 2025. PMID 41207310; DOI 10.1016/S0140-6736(25)02155-5. Peer-reviewed trial; abstract checked. Funded by Eli Lilly.
2. ClinicalTrials.gov: NCT06230523, Phase 2 study and posted results. Registry results and denominators checked through the public API; results first posted June 24, 2026.
3. Briere DA et al. From discovery to clinical proof of concept. Molecular Metabolism, 2025. PMID 41109426; DOI 10.1016/j.molmet.2025.102271. Laboratory, animal and early human findings; abstract checked.
4. Eli Lilly: What to know about eloralintide, September 2026 update. Sponsor explanation of mechanism, investigational status and the combination; not independent clinical validation.
5. ClinicalTrials.gov: ENLIGHTEN-1, NCT07321886. Registry checked November 11, 2026; last posted update September 22, 2026.
6. ClinicalTrials.gov: ENLIGHTEN-2, NCT07282600. Registry checked November 11, 2026; last posted update November 4, 2026.
7. Eli Lilly: Phase 2 monotherapy announcement, November 6, 2025. Sponsor decimals and efficacy-estimand explanation, retained separately from registry results.
8. Bhattachar SN et al. Phase 1 proof of concept. Diabetes, Obesity and Metabolism, 2026. PMID 41559929; DOI 10.1111/dom.70439. Peer-reviewed 12-week study; abstract checked.
9. Lilly HCP: Eloralintide plus tirzepatide Phase 2 results, EASD, September 30, 2026. Sponsor-hosted conference presentation; population and analyses differ from the monotherapy publication.

How this page was prepared: The Peptide Dossier Editorial Team used AI-assisted drafting and checked the cited primary abstracts, public registry records and sponsor materials. This is an editorial evidence synthesis, not a systematic review or clinician review. Sources were checked November 11, 2026. See our editorial policy and about page for attribution and corrections.